Your browser doesn't support javascript.
loading
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).
Aakash, Fnu; Gisriel, Savanah D; Zeidan, Amer M; Bennett, John M; Bejar, Rafael; Bewersdorf, Jan Philipp; Borate, Uma M; Boultwood, Jacqueline; Brunner, Andrew M; Buckstein, Rena; Carraway, Hetty E; Churpek, Jane E; Daver, Naval G; DeZern, Amy E; Efficace, Fabio; Fenaux, Pierre; Figueroa, Maria E; Garcia-Manero, Guillermo; Gore, Steven D; Greenberg, Peter L; Griffiths, Elizabeth A; Halene, Stephanie; Hourigan, Christopher S; Kim, Tae Kon; Kim, Nina; Komrokji, Rami S; Kutchroo, Vijay K; List, Alan F; Little, Richard F; Majeti, Ravindra; Nazha, Aziz; Nimer, Stephen D; Odenike, Olatoyosi; Padron, Eric; Patnaik, Mrinal M; Platzbecker, Uwe; Della Porta, Matteo G; Roboz, Gail J; Sallman, David A; Santini, Valeria; Sanz, Guillermo; Savona, Michael R; Sekeres, Mikkael A; Stahl, Maximilian; Starczynowski, Daniel T; Steensma, David P; Taylor, Justin; Abdel-Wahab, Omar; Wei, Andrew H; Xie, Zhuoer.
Afiliación
  • Aakash F; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology, University of Texas Medical Branch, Galveston, Texas.
  • Gisriel SD; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
  • Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.
  • Bennett JM; James P. Wilmot Cancer Center, Division of Hematopathology, University of Rochester Medical Center, Rochester, New York.
  • Bejar R; Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, California.
  • Bewersdorf JP; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Borate UM; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Boultwood J; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Brunner AM; Division of Hematology, Massachusetts General Hospital Brigham, Boston, Massachusetts.
  • Buckstein R; Division of Medical Oncology/Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Carraway HE; Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
  • Churpek JE; Division of Haematology, Oncology, and Palliative Care, Department of Medicine, Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
  • Daver NG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • DeZern AE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland.
  • Efficace F; Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy.
  • Fenaux P; Service d'hématologie, Hôpital Saint-Louis (Assistance Publique Hôpitaux de Paris), Université de Paris-Cité, Paris, France.
  • Figueroa ME; Biochemistry & Molecular Biology, Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine, Miami, Florida.
  • Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gore SD; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland.
  • Greenberg PL; Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Griffiths EA; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Halene S; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.
  • Hourigan CS; Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, District of Columbia.
  • Kim TK; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Kim N; NCI, NIH, Bethesda, Maryland.
  • Komrokji RS; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Kutchroo VK; Brigham and Women's Hospital, Boston, Massachusetts.
  • List AF; Chief Scientific Officer, Stelexis Therapeutics, New York, New York.
  • Little RF; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland.
  • Majeti R; Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Nazha A; Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Nimer SD; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
  • Odenike O; Leukemia Program, Section of Hematology/Oncology, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
  • Padron E; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
  • Platzbecker U; Department of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
  • Della Porta MG; IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Roboz GJ; Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
  • Sallman DA; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Santini V; Myelodysplastic Syndromes Unit, Department of Experimental and Clinical Medicine, Hematology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.
  • Sanz G; Health Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain.
  • Savona MR; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Sekeres MA; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
  • Stahl M; Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Starczynowski DT; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio.
  • Steensma DP; David Steensma LLC, Cambridge, Massachusetts.
  • Taylor J; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
  • Abdel-Wahab O; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Wei AH; Department of Haematology, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia.
  • Xie Z; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Mod Pathol ; 37(12): 100615, 2024 Sep 23.
Article en En | MEDLINE | ID: mdl-39322118
ABSTRACT
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization Classification of Haematolymphoid tTumours and the International Consensus Classification) further subcharacterized MDS into morphologically and genetically defined groups. Accurate diagnosis and subclassification of MDS require a multistep systemic approach. The International Consortium for MDS (icMDS) summarizes a contemporary, practical, and multimodal approach to MDS diagnosis and classification.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mod Pathol Asunto de la revista: PATOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mod Pathol Asunto de la revista: PATOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos